1. Genital HPV Infection –CDC Fact Sheet. Published July 2017. Accessed September 2, 2020. https://www.cdc.gov/std/hpv/HPV-FS-July-2017.pdf. 2. Saslow D, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. Am J Clin Pathol. 2012;137:516-542. 3. Tinelli A, et al. HPV viral activity by mRNA HPV molecular analysis to screen the transforming infections in precancer cervical lesions. Curr Pharm Biotechnol. 2009;10(8):767-771. 4. Cuschieri K, et al. Human Papillomavirus Type Specific DNA and RNA Persistence–Implications for Cervical Disease Progression and Monitoring. J Med Virol. 2004;73(1):6570.doi:10.1002/jmv.20062 5. Szarewski A, et al. Comparison of predictors for high grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev. 2008;17(11):3033-3042.6. Dockter J, et al. Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions. J Clin Virol. 2009;45(S1):S55-S61. 7. Reuschenbach M, et al. Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results. Gynecol Oncol. 2010;119(1):98-105. 8. Clad A, et al. Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology. J Clin Microbiol. 2011;49(3):1071-1076. 9. Ratnam S, et al. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 assay but more specific at detecting cervical precancer and cancer. J Clin Microbiol. 2011;49(2):557-564.10. Aptima HPV Assay [package insert]. AW-12820, Rev.004. San Diego, CA; Hologic, Inc., 2017.11. Ovestad IT, et al. Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3. Gynecol Oncol. 2011;123(2):278-283.12. Szarewski A, et al. Comparison of seven tests for highgrade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J Clin Microbiol. 2012; 50(6):1867-1873.13. Eaton, et al. Comparison of the Aptima HPV assay and the cobas HPV test in an ASC-US population [abstract]. Paper presented at: 28th International Papillomavirus Conference. November 30-December 6, 2017. San Juan, Puerto Rico.14. Cuschieri K, et al. Clinical performance of RNA and DNA based HPV testing in a colposcopy setting: Influence of assay target, cut off and age. J Clin Virol. 2014;59(2):104-108.15. Cubie HA, et al. Evaluation of commercial HPV assays in the context of post-treatment follow-up: Scottish Test of Cure Study (STOCS-H). J Clin Pathol. 2014;67(6):458-463.16. Binniker M, et al. Comparative evaluation of three commercial systems for the detection of high-risk human papillomavirus in cervical and vaginal ThinPrep PreservCyt samples with biopsy correlation. J Clin Microbiol. 2014;52(10):3763-8.17. Castle P, et al. Comparison of human papillomavirus detection by Aptima HPV and cobas HPV Tests in a population of women referred for colposcopy following detection of atypical squamous cells of undetermined significance by pap cytology. J Clin Microbiol. 2015;53(4):1277-1281.18. Cuzick J, et al. A comparison of different human papillomavirus tests in PreservCyt versus SurePath in a referral population—PREDICTORS 4. J Clin Virology. 2016;82:145-151.19.Virtanen E, et al. Performance of mRNA-and DNA-based high-risk human papillomavirus assays in detection of high-grade cervical lesions. Acta Obstetricia et Gynecologica Scandinavica. 2017; 96(1):61-68.20. Wu R, et al. Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen Cervical Cancer Screening Trial I. Intl J Gynecol Cancer. 2010;20(8):1411-1414. 21. Monsonego J, et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study. Intl J Cancer. 2011;129(3):691-701. 22. Iftner, et al. Comparison of Aptima and HC2 in a routine screening trial in Germany with follow up [abstract]. Paper presented at: 28th International Papillomavirus Conference; November 30-December 6, 2012; San Juan, Puerto Rico. 23. Cuzick J, et al. Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer. 2013;108:908-913. 24. Nieves L, et al. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.Int J Gynecol Cancer.2013;23(3):513-518. 25. Iftner T, et al. Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany. J Clin Microbiol. 2015;53(8):2509-2516. 26. American Society for Colposcopy and Cervical Pathology. 2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and CancerPrecursors.J Low Genit Tract Dis.2013;17(5):S1-S27. 27. Morris BJ. Clin Chem Lab Med. 2005;43(11):1171-7. doi:10.1515/ CCLM.2005.203.28. De Sanjose et al.Lancet Oncol.2010;11(11):1048-56. doi: 10.1016/S1470-2045(10)70230-8. 29. Wheeler CM, et al. J Natl Cancer Inst.2009;101(7):475-87. doi:10.1093/jnci/djn510. 30. Coutlée F, et al. J MedVirol. 2011;83(6):1034-41. doi:10.1002/jmv.22081. 31. Hybrid Capture 2 [package insert]. #L00665. QIAGEN, Inc. 32.Cobas c4800 [package insert]. #05641268001-0N. Roche Molecular Systems, Inc. 33. Iftner T, et al. The longitudinal clinical performance of the RNA-based AHPV Human Papillomavirus (HPV) Assay in comparison to the DNA-based Hybrid Capture 2 HPV Test in 2 consecutive screening rounds with a 6-year interval inGermany. J Clin Microbiol. 2018. doi:10.1128/JCM.01177-18 (GAST) 34. Forslund O, et al. HPV-mRNA and HPV-DNA detection in samples taken up to seven years before dysplasia of cervix uteri. Int J Cancer. 2018; doi: 10.1002/ijc.31819